Vincentage posts phase 3 win for oral weight-loss drug VCT220: full analysis
Vincentage Pharma has reported positive topline Phase 3 results for VCT220, a once-daily oral small-molecule GLP-1 receptor agonist for weight management, and said it plans to submit a near-term NDA to China’s National Medical Products Administration. In the pivotal study, adults in China with obesity, or who were overweight with at least one weight-related comorbidity, lost an average of 12.2% to 12.4% of body weight at 52 weeks on VCT220, compared with 1.3% on placebo. (globenewswire.com)
The program has been building toward this readout for more than a year. Corxel, which holds global ex-China rights to the molecule as CX11, highlighted positive Phase 2 China data in June 2025 and said at that point that the registrational Phase 3 trial in China had already started in November 2024. In that earlier randomized study, weight loss at week 16 ranged from 5.8% to 9.7% across dose cohorts, versus 1.6% with placebo, and investigators reported improvements in measured cardiometabolic markers including blood pressure and liver enzymes. (corxelbio.com)
In the Phase 3 trial, Vincentage said 840 adults were enrolled in a multicenter, randomized, double-blind, placebo-controlled study. Eligible participants had a BMI of at least 28 kg/m², or a BMI of 24 to less than 28 kg/m² with at least one obesity-related comorbidity. The company described VCT220 as an oral, non-peptide GLP-1 therapy designed for once-daily use without food or water restrictions, fixed dosing-time requirements, refrigeration, or light-protected storage, all positioning points meant to differentiate it from some existing GLP-1 options. (globenewswire.com)
On safety, Vincentage said the profile was consistent with the broader GLP-1 class. Gastrointestinal adverse events were the most common and were generally mild to moderate, with no severe nausea or vomiting reported. Fierce Biotech, citing the company’s release, reported that 1.8% of treated patients discontinued because of treatment-related adverse events. (globenewswire.com)
Industry framing around the result has centered on competition in the oral obesity market. Vincentage’s principal investigator, Ji Linong of Peking University People’s Hospital, said VCT220 is the second oral non-peptide small-molecule GLP-1 receptor agonist globally to complete a pivotal Phase 3 obesity trial and be ready for NDA submission, after Eli Lilly’s orforglipron. External coverage has similarly cast the result as another sign that China-based developers are trying to narrow the gap with multinational obesity drug leaders. (globenewswire.com)
Why it matters: For veterinary professionals, this is less about a direct animal-health application and more about the broader obesity-treatment landscape that shapes pet parent awareness and expectations. As human medicine puts more emphasis on chronic weight management, oral dosing convenience, and long-term adherence, veterinary teams may see more questions about whether similar pharmacologic approaches could eventually influence companion-animal obesity care. It also reinforces how obesity is being treated increasingly as a chronic metabolic disease, not just a lifestyle issue, a framing that overlaps with how many veterinary teams already approach weight management counseling. The caveat is important: there’s no indication here that VCT220 is being developed for veterinary use, and cross-species assumptions would be premature. (globenewswire.com)
What to watch: The next milestones are a formal NMPA submission in China and the U.S. Phase 2 readout for CX11 later in 2026, which should give a clearer sense of whether Vincentage and Corxel can translate this China registrational momentum into a broader global obesity program. (globenewswire.com)